Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study

被引：0
|
作者：
Cano-Smith, J. [1 ]
Delgado-Hierro, A. [1 ]
Valencia, E. [1 ]
Ramos, L. [1 ]
Busca, C. [1 ]
Mican, R. [1 ]
Martin-Carbonero, L. [1 ,2 ]
Montes, M. L. [1 ,2 ]
De Miguel, R. [1 ,2 ]
Montejano, R. [1 ]
Moreno, V. [1 ]
Perez-Sadaba, F. [3 ]
Perez-Rambla, C. [3 ]
Molina, R. [4 ]
Gonzalez-Garcia, J. [1 ]
Bernardino, J. I. [1 ]
机构：
[1] Hosp La Paz Carlos III, HIV Unit, IdiPaz, Dept Internal Med, Madrid, Spain
[2] Ctr Invest Biomed Red Enfermedades Infecciosas CI, Madrid, Spain
[3] Outcomes 10 SLU, Castellon De La Plana, Spain
[4] Fdn SEIMC GESIDA, Madrid, Spain
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：411 / 412
页数：2
相关论文
共 50 条
  • [1] Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study
    Esser, S.
    Trottier, B.
    Antinori, A.
    Hila, E.
    Antela, A.
    Tigen, E. Tukenmez
    Boffito, M.
    Lambert, J. S.
    van Welzen, B. J.
    Mack, F.
    Schreiber, S.
    Cassidy, T.
    Harrison, R.
    Saifi, T.
    Sabranski, M.
    Vassallo, M.
    HIV MEDICINE, 2023, 24 : 412 - 414
  • [2] Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence
    Boffito, Marta
    Brunetta, Jason
    Levy, Itzchak
    Yang, Chia-Jui
    Portilla, Joaquin
    De Barra, Eoghan
    Vogelmann, Roger
    Endo, Tomoyuki
    Robineau, Olivier
    Sarmati, Loredana
    Thorpe, David
    Marongiu, Andrea
    Cassidy, Tali
    van Welzen, Berend
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 79 - 82
  • [3] Bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in antiretroviral treatment-naive (TN) and -experienced (TE) people with HIV (PWH): 3-year effectiveness and safety outcomes in the BICSTaR observational cohort
    Sabranski, M.
    Vassallo, M.
    de Wet, J.
    Rieke, A.
    Wong, A.
    Thorpe, D.
    Cassidy, T.
    Marongiu, A.
    Robineau, O.
    HIV MEDICINE, 2023, 24 : 84 - 87
  • [4] Four-year outcomes from the BICSTaR study: observational analysis of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive (TN) and treatment-experienced (TE) people with HIV in Canada, France and Germany
    Wong, Alex
    Beer, Daniel
    Duvivier, Claudine
    Cordel, Hugues
    Meurer, Anja
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Ramroth, Johanna
    Trottier, Benoit
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 73 - 74
  • [5] 24-Month (24M) effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive (TN) and treatment-experienced (TE) people living with HIV in the BICSTaR study
    Garcia-Deltoro, Miguel
    Waizmann, Michael
    Robineau, Olivier
    Wong, Alexander
    Shahar, Eduardo
    Lambert, John S.
    van Welzen, Berend
    Boffito, Marta
    Yokomaku, Yoshiyuki
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Heinzkill, Marion
    Lluis-Ganella, Carla
    Di Perri, Giovanni
    HIV MEDICINE, 2023, 24 : 23 - 23
  • [6] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
    Yokomaku, Yoshiyuki
    Teruya, Katsuji
    Watanabe, Dai
    Endo, Tomoyuki
    Minami, Rumi
    Taguchi, Nao
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Shirasaka, Takuma
    Oka, Shinichi
    PLOS ONE, 2025, 20 (01):
  • [7] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
    Busca, C.
    Ortega, D.
    Martin-Carbonero, L.
    Mican, R.
    Ramos, L.
    Valencia, M.
    Montejano, R.
    Montes, M.
    Diaz-Almiron, M.
    Delgado, A.
    Bernardino, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
  • [8] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV
    Hill, L.
    Momper, J.
    Abulhosn, K.
    Ballard, C.
    Young, M.
    HIV MEDICINE, 2019, 20 : 81 - 81
  • [9] Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study
    Wong, Alexander
    Brunetta, Jason
    De Wet, Joss
    Logue, Ken
    Loemba, Hugues
    Saifi, Taban
    Mumm, Dylana
    Marongiu, Andrea
    Harrison, Rebecca
    Thorpe, David
    Trottier, Benoit
    MEDICINE, 2024, 103 (16) : E37785
  • [10] Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naı<spacing diaeresis>ve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study
    Tseng, Yu-Ting
    Yang, Chia-Jui
    Kim, Yeon-Sook
    Choi, Jun Yong
    Wong, Chen Seong
    Lee, Kuan-Yeh
    Lee, Jeong-a
    Chang, Jack
    Harrison, Rebecca
    Marongiu, Andrea
    Lee, Sun Hee
    Hung, Chien-Ching
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2024, 57 (05) : 760 - 770
12345